Erythropoietin (EPO) ELISA试剂盒-ACROBiosystems百普赛斯

ClinMax™ Human Erythropoietin (EPO) ELISA Kit, PRO

原理（Assay Principles）

背景（Background）

ClinMax™ ELISA Kit is convenient ready-to-use immunoassay Kit, specifically designed to quantitate human EPO that is present in complex biological samples, such as human serum, plasma, and cell culture supernates.

A comprehensive validation of the ELISA method was performed following the ICH M10 on bioanalytical method validation and the FDA’s bioanalytical method validation guidance for industry. This validation included assessments of linearity, accuracy, precision, dilution linearity, recovery, and the hook effect. For details information, please refer to the DS.

ClinMax™ ELISA Kits are manufactured in a GMP-like facility and comply to the ISO 13485 standard, ensuring a high level of quality and reliability.

应用说明（Application）

The kit is developed for quantitative detection of human EPO in serum and plasma.

It is for research use only.

重构方法（Reconstitution）

Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.

存储（Storage）

Keep the unopened kit stored at 2-8 °C. Avoid using the kit beyond its expiration date. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

用户评价

背景（Background）：EPO

Erythropoietin (EPO) is a glycoprotein hormone, naturally produced by the peritubular cells of the kidney, that stimulates red blood cell production. Renal cortex peritubular cells produce most EPO in the human body. PO2 directly regulates EPO production. The lower the pO2, the greater the production of EPO. Erythropoietin stimulating agents (ESAs) are recombinant versions of EPO produced pharmacologically. Examples of ESAs are epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin beta. ESAs are generally indicated in conditions where there is impaired red blood cell production. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of ESAs in light of the natural physiology of erythropoietin, pertinent for members of the interprofessional team in the treatment of patients with conditions where these agents are indicated.